Ryzodeg® passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan
3 December 2012 | By Novo Nordisk
Novo Nordisk announced that Ryzodeg® has passed the review...
List view / Grid view
3 December 2012 | By Novo Nordisk
Novo Nordisk announced that Ryzodeg® has passed the review...
3 December 2012 | By Merck
Merck has started a Phase II/III clinical trial...
3 December 2012 | By Merck
Merck & The JAMA Network announced a new collaboration to enhance the medical information available...
30 November 2012 | By Johnson & Johnson
Bill Weldon to step down after 41-year career at Johnson & Johnson...
29 November 2012 | By HACH LANGE
Lab & process instrumentation at discounted prices. At this time of year, HACH LANGE sells off its current demo stock at discounted prices...
29 November 2012 | By Merck
Merck has notified the EMA of Merck's decision to withdraw the MAA for ridaforolimus...
29 November 2012 | By Biogen Idec
Biogen Idec dedicated a new facility in Research Triangle Park (RTP), consolidating its 300-person Patient Services operation with the existing RTP campus...
29 November 2012 | By Virgo HEALTH
NextPharma Technologies Holding Limited is pleased to announce the sale of Bioserv Corporation...
28 November 2012 | By Citigate Dewe Rogerson Ltd
Genzyme appointed Brendan Martin as General Manager for UK and Ireland...
28 November 2012 | By Sanofi
Sanofi ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index)...
28 November 2012 | By Novartis
More than 140 presentations on key data...
28 November 2012 | By GlaxoSmithKline
GSK welcomes the publication of the third Access to Medicines (ATM) Index...
28 November 2012 | By Catalent Pharma Solutions
Jeffrey E. Browne at Catalent Pharma Solutions will be presenting...
28 November 2012 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc..
28 November 2012 | By Abbott
Abbott board of directors approved the separation of its research-based pharmaceuticals business...